NuVasive has been the global leader in lateral spine surgery for more than 15 years, built on the foundation of the Company's XLIF procedure that is supported by extensive clinical evidence with more than 400 peer-reviewed publications. XLIF is part of the Company's offerings to help surgeons adopt more efficient, less disruptive surgical approaches to spine procedures, which have been shown to reduce blood loss, postoperative hospital stay, and result in less operative morbidity compared to open spine surgery.1,2